CAR T therapies in multiple myeloma: Unleashing the future
M Sheykhhasan, A Ahmadieh-Yazdi… - Cancer Gene …, 2024 - nature.com
In recent years, the field of cancer treatment has witnessed remarkable breakthroughs that
have revolutionized the landscape of care for cancer patients. While traditional pillars such …
have revolutionized the landscape of care for cancer patients. While traditional pillars such …
Chemical genetic control of cytokine signaling in CAR-T cells using lenalidomide-controlled membrane-bound degradable IL-7
MC Kann, EM Schneider, AJ Almazan, IC Lane… - Leukemia, 2024 - nature.com
CAR-T cell therapy has emerged as a breakthrough therapy for the treatment of relapsed
and refractory hematologic malignancies. However, insufficient CAR-T cell expansion and …
and refractory hematologic malignancies. However, insufficient CAR-T cell expansion and …
Targeting Multiple Myeloma Resistant to T Cell Redirection Therapies
ALH Keller - 2024 - search.proquest.com
Multiple myeloma (MM) is a plasma cell malignancy characterized by multi-drug resistance.
Recently, T cell redirection therapies (TCRTs) including T cell engagers (TCEs) and CAR-T …
Recently, T cell redirection therapies (TCRTs) including T cell engagers (TCEs) and CAR-T …